Background: It has been suggested that coronary artery disease (CAD) is a common complicating condition in pulmonary fibrosis.
Objective: To establish and compare the incidence of coronary artery disease in lung-transplantation candidates with emphysema and lung fibrosis
Method: All adult patients (age>40 years old) with emphysema or lung fibrosis, candidates for lung transplantation between January 1997 and December 2003, were included. All patients underwent pretransplant coronary angiography.
Results: A total of 100 patients were enrolled; 51 with emphysema and 49 with fibrosis. CAD (at least one 50% stenotic coronary artery) was diagnosed in fourteen of 49 (28.6%) patients with lung fibrosis as compared to five out of 51 (9.8%) with emphysema, [p=0.019] despite the fact that 98% of patients with emphysema but only 31% of the patients with lung fibrosis were heavy smokers. The groups didn't significantly differ in any other cardiovascular risks.
Conclusions: There is significantly more CAD in lung-transplantation candidates with lung fibrosis as compared to those with emphysema, despite the fact that smoking was much more prevalent in the emphysema patients. These results suggest that the inflammatory process in lung fibrosis may involve the coronary arteries as a part of a systemic inflammation rather than an idiopathic fibrotic disease confined to the lungs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.rmed.2009.03.012 | DOI Listing |
Ann Rheum Dis
January 2025
Department of Rheumatology, Université Paris Cité UFR de Médecine, Paris, France.
Objectives: To update the 2017 European Alliance of Associations for Rheumatology (EULAR) recommendations for treatment of systemic sclerosis (SSc), incorporating new evidence and therapies.
Methods: An international task force was convened in line with EULAR standard operating procedures. A nominal group technique exercise was performed in two rounds to define questions underpinning a subsequent systematic literature review.
FASEB J
January 2025
Stem Cell and Biotherapy Technology Research Center, School of Life Science and Technology, Xinxiang Medical University, Xinxiang, China.
Pulmonary fibrosis (PF) is a chronic and progressive interstitial lung disease characterized by abnormal activation of myofibroblasts and pathological remodeling of the extracellular matrix, with a poor prognosis and limited treatment options. Lung transplantation is currently the only approach that can extend the life expectancy of patients; however, its applicability is severely restricted due to donor shortages and patient-specific limitations. Therefore, the search for novel therapeutic strategies is imperative.
View Article and Find Full Text PDFFEBS Lett
January 2025
Department of Microbiology and Immunology, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Tissue fibrosis is a progressive pathological process with excessive deposition of extracellular matrix proteins (ECM). Myofibroblasts, identified by alpha-smooth muscle actin (αSMA) expression, play an important role in tissue fibrosis by producing ECM. Here, we found that the Wnt antagonist Dickkopf1 (DKK1) induced gene expressions associated with inflammation and fibrosis in lung fibroblasts.
View Article and Find Full Text PDFEur Clin Respir J
January 2025
Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Queensland, Australia.
Therapeutic drug monitoring (TDM) of elexacaftor/tezacaftor/ivacaftor (ETI) remains challenging due to a lack of clarity around the parameters that govern ETI plasma concentrations, whilst the use of concomitant CYP3A inducers rifabutin and rifampicin is not recommended. We present the complexities of TDM for ETI performed in a person with cystic fibrosis and refractory pulmonary disease. Utilising National Association of Testing Authorities (NATA) accredited assays and target considerations published by the Therapeutic Goods Administration (TGA), Australia, ETI plasma concentration variability was monitored over the course of an acute admission with added complexity from an antibiotic regimen including rifabutin, a moderate cytochrome P450 3A (CYP3A) inducer, and clofazimine, a mild CYP3A inhibitor.
View Article and Find Full Text PDFFront Immunol
January 2025
Laboratory of Molecular Immunology, Institute of Molecular Biology, Slovak Academy of Sciences, Bratislava, Slovakia.
Introduction: Diffuse parenchymal lung diseases (DPLD) cover heterogeneous types of lung disorders. Among many pathological phenotypes, pulmonary fibrosis is the most devastating and represents a characteristic sign of idiopathic pulmonary fibrosis (IPF). Despite a poor prognosis brought by pulmonary fibrosis, there are no specific diagnostic biomarkers for the initial development of this fatal condition.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!